MEDtalk: KEYNOTE 590 will change practice for patients with oesophagus Cancer

Ken Kato | Syys 2020 | ESMO 2020 |

Ken Kato
MD. PhD,
Chief of The Department of Head,
Neck and Esophageal Medical Oncology,
National Cancer Center,
Tokyo, Japan

The KEYNOTE 590 trial examined first-line chemotherapy, with or without pembrolizumab, in patients with squamous cell carcinoma of the oesophagus, adenocarcinoma of the oesophagus, or Siewert type 1 gastro-oesophageal junction adenocarcinoma. In this MEDtalk Ken Kato, MD. PhD, National Cancer Center Hospital, Tokyo, presents the results of the KEYNOTE 590 study.